Telintra is currently in Phase II clinical trials for the treatment of myelodysplastic syndrome, a form of pre-leukemia, and for chemotherapy induced neutropenia, a common side effect of chemotherapy.
Telik expects these applications and patents to provide broad intellectual property protection to compounds related to Telintra. The patents will help to broaden and strengthen Telik’s intellectual property estate and may support additional clinical development candidates.